Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.

Auvin S, Öztürk H, Abaci YT, Mautino G, Meyer-Losic F, Jollivet F, Bashir T, de Thé H, Sahin U.

Life Sci Alliance. 2019 Aug 20;2(4). pii: e201800213. doi: 10.26508/lsa.201800213. Print 2019 Aug.

2.

Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.

Nakhlé J, Pierron V, Bauchet AL, Plas P, Thiongane A, Meyer-Losic F, Schmidlin F.

Oncoimmunology. 2016 Feb 18;5(6):e1145333. doi: 10.1080/2162402X.2016.1145333. eCollection 2016 Jun.

3.

STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.

Meyer-Losic F, Newman SP, Day JM, Reed MJ, Kasprzyk PG, Purohit A, Foster PA.

PLoS One. 2013 Dec 6;8(12):e80305. doi: 10.1371/journal.pone.0080305. eCollection 2013.

4.

DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.

Meyer-Losic F, Nicolazzi C, Quinonero J, Ribes F, Michel M, Dubois V, de Coupade C, Boukaissi M, Chéné AS, Tranchant I, Arranz V, Zoubaa I, Fruchart JS, Ravel D, Kearsey J.

Clin Cancer Res. 2008 Apr 1;14(7):2145-53. doi: 10.1158/1078-0432.CCR-07-4580.

5.

Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.

Ravel D, Dubois V, Quinonero J, Meyer-Losic F, Delord J, Rochaix P, Nicolazzi C, Ribes F, Mazerolles C, Assouly E, Vialatte K, Hor I, Kearsey J, Trouet A.

Clin Cancer Res. 2008 Feb 15;14(4):1258-65. doi: 10.1158/1078-0432.CCR-07-1165.

6.

Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).

Meyer-Losic F, Quinonero J, Dubois V, Alluis B, Dechambre M, Michel M, Cailler F, Fernandez AM, Trouet A, Kearsey J.

J Med Chem. 2006 Nov 16;49(23):6908-16.

PMID:
17154520
7.

Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.

Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Malivet V, Chacun C, Jan M, Tillequin F, Michel S, Koch M, Pfeiffer B, Atassi G, Hickman J, Pierré A.

Clin Cancer Res. 2001 Aug;7(8):2573-80.

8.

[New approaches in experimental cancerology: in search of therapeutic models].

Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Pierré A, Hickman J.

Bull Cancer. 2001 Jan;88(1):75-84. French. No abstract available.

Supplemental Content

Loading ...
Support Center